Lexaria executing a triple-pronged strategy in obesity and diabetesSemaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
Targeting NDA submission for bitopertin in erythropoietic protoporphyria (EPP) in H2 2025 through accelerated approval pathway; on track to initiate APOLLO post-marketing confirmatory trial by mid-202 ...
A study of 151 patients with carbapenem-nonsusceptible infections found treatment with imipenem/cilastatin/relebactam was ...
1h
HealthDay on MSNEnvironmental Health Expert Gives FDA an ‘F’ for Its Handling of Chemicals in Our Food. His Advice on How to Lower Your ExposureHi, I’m Dr. Robin Miller for HealthDay.PFAS, also known as forever chemicals, are in the blood of nearly all Americans. We’re exposed to them when we use certai ...
9hOpinion
Zacks.com on MSNTop 3 Medical Instruments Industry Stocks to Ride the GenAI BoomOver the past year, advancements in AI and predictive analytics have rapidly revolutionized the Medical Instruments industry, ...
Over 101,000 Americans need a kidney transplant, but only 17,000 people receive one each year due to a donated organ shortage ...
China NMPA approves Fosun Pharma’s tenapanor hydrochloride tablets to control of serum phosphorus levels in dialysis patients with CKD: Shanghai, China Thursday, February 27, 20 ...
SGLT2 inhibitors reduce the risk of kidney failure in patients with Type 2 diabetes and advanced chronic kidney disease, ...
4h
Everyday Health on MSNBrewing Tea Helps Remove Lead and Other Harmful Heavy Metals From WaterA new study has found that heavy metals stick to tea leaves and bags while steeping, which could reduce exposure to dangerous ...
Lexaria executing a triple-pronged strategy in obesity and diabetes Semaglutide recently approved to treat chronic kidney disease KELOWNA, BC / ACCESS Newswire / February 27, 2025 / Lexaria Bioscience ...
A progressive approach to drug approval would balance the reality of drug safety and efficacy research with the desire to get ...
ACCESS and ACCESS II studies fully enrolled; topline data from both studies anticipated by year-end 2025Oral small ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results